共 42 条
[1]
Kirby A(2020)Practice patterns for women with overactive bladder syndrome: time between medications and third-line treatments Female Pelvic Med Reconstr Surg 26 431-436
[2]
Park S(2013)The management of overactive bladder refractory to medical therapy Maturitas. 75 101-104
[3]
Robinson D(2016)Overactive bladder Obstet Gynecol Clin N Am 43 59-68
[4]
Giarenis I(2020)Evaluation and treatment of overactive bladder in women Mayo Clin Proc 95 370-377
[5]
Cardozo L(2018)Two-year outcomes of sacral neuromodulation versus OnabotulinumtoxinA for refractory urgency urinary incontinence: a randomized trial Eur Urol 74 66-73
[6]
White N(2018)Efficacy and safety of sacral and percutaneous Tibial neuromodulation in non-neurogenic lower urinary tract dysfunction and chronic pelvic pain: a systematic review of the literature Eur Urol 73 406-418
[7]
Iglesia CB(2010)Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial J Urol 184 2416-2422
[8]
Raju R(2014)Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder BJUI. 113 484-491
[9]
Linder BJ(2015)Affective symptoms and the overactive bladder - a systematic review J Psychosom Res 78 95-108
[10]
Amundsen CL(2018)Use of third line therapy for Overactive Bladder in a practice with multiple subspecialty providers-are we doing enough? J Urol 199 779-784